| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23071 |
| Drug | Ritlecitinib |
| Brand | Litfulo® |
| Indication | For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
| Assessment Process | |
| Rapid review commissioned | 27/11/2023 |
| Rapid review resubmission required | 11/12/2023 |
| Rapid review completed | 22/12/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2024 |
| Pre-submission consultation with Applicant | 10/09/2024 |
| Full submission received from Applicant | 11/02/2025 |
| Preliminary review sent to Applicant | 12/08/2025 |
| NCPE assessment re-commenced | 10/09/2025 |
| Factual accuracy sent to Applicant | 24/10/2025 |
| NCPE assessment re-commenced | 03/11/2025 |
| Follow up to factual accuracy check sent to Applicant | 11/11/2025 |
| NCPE assessment re-commenced | 28/11/2025 |
| NCPE assessment completed | 02/12/2025 |
| NCPE assessment outcome | The NCPE recommends that ritlecitinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.